Literature DB >> 10589952

Susceptibility of lung transplants to preformed donor-specific HLA antibodies as detected by flow cytometry.

J C Scornik1, D S Zander, M A Baz, W H Donnelly, E D Staples.   

Abstract

BACKGROUND: Preformed anti-HLA antibodies are known to have the potential to induce early graft damage in organ transplant recipients. However, in lung transplant recipients, little information exists about the significance of preformed antibodies directed to either class I or class II HLA antigens.
METHODS: A two-color flow cytometry cross-match was performed in 92 consecutive lung transplant recipients using serum obtained immediately before transplantation. The presence of preformed antibodies was correlated with the incidence of severe graft dysfunction manifested as pulmonary infiltrates and severe hypoxemia with onset in the first few hours after transplantation.
RESULTS: Six patients (6.5%) had low-level anti-donor IgG antibodies detected by flow cytometry, four against T and two against B lymphocytes. Three patients (50%) developed severe graft dysfunction with pulmonary infiltrates and hypoxemia. Two patients responded to treatment, but the third, who had an antibody highly specific for HLA-DR11, died at 48 hr after transplant. Results of histopathologic studies in this patient are consistent with hyperacute rejection and support a pathogenic role of these antibodies. In contrast, of 86 (93.5%) cases with a negative flow cytometry cross-match, only 4 (5%) had severe but reversible early graft dysfunction with pulmonary infiltrates and hypoxemia, attributed to ischemia-reperfusion injury (P<0.005).
CONCLUSIONS: Class II, and perhaps class I HLA antibodies at relatively low concentrations represent a risk factor for severe early pulmonary graft dysfunction, with the potential to progress to hyperacute rejection and death.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10589952     DOI: 10.1097/00007890-199911270-00018

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

1.  HLA class I sensitization in islet transplant recipients: report from the Collaborative Islet Transplant Registry.

Authors:  Bashoo Naziruddin; Steve Wease; Donald Stablein; Franca B Barton; Thierry Berney; Michael R Rickels; Rodolfo Alejandro
Journal:  Cell Transplant       Date:  2011-11-11       Impact factor: 4.064

2.  Immunoglobulin (Ig)G purified from human sera mirrors intravenous Ig human leucocyte antigen (HLA) reactivity and recognizes one's own HLA types, but may be masked by Fab complementarity-determining region peptide in the native sera.

Authors:  M H Ravindranath; P I Terasaki; C Y Maehara; V Jucaud; S Kawakita; T Pham; W Yamashita
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

3.  Antibody-mediated Rejection in Lung Transplantation.

Authors:  Hrishikesh S Kulkarni; Bradford C Bemiss; Ramsey R Hachem
Journal:  Curr Transplant Rep       Date:  2015-09-30

4.  Increased erythrocyte C4D is associated with known alloantibody and autoantibody markers of antibody-mediated rejection in human lung transplant recipients.

Authors:  Angali Golocheikine; Dilip S Nath; Haseeb Ilias Basha; Deepti Saini; Donna Phelan; Aviva Aloush; Elbert P Trulock; Ramsey R Hachem; G Alexander Patterson; Joseph M Ahearn; Thalachallour Mohanakumar
Journal:  J Heart Lung Transplant       Date:  2010-04       Impact factor: 10.247

Review 5.  Bronchiolitis obliterans syndrome: the Achilles' heel of lung transplantation.

Authors:  S Samuel Weigt; Ariss DerHovanessian; W Dean Wallace; Joseph P Lynch; John A Belperio
Journal:  Semin Respir Crit Care Med       Date:  2013-07-02       Impact factor: 3.119

6.  Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR,DQ,DP epitopes.

Authors:  Rene J Duquesnoy; Yehia Awadalla; Jon Lomago; Larry Jelinek; Judy Howe; Dwayne Zern; Betty Hunter; Joan Martell; Alin Girnita; Adriana Zeevi
Journal:  Transpl Immunol       Date:  2007-10-30       Impact factor: 1.708

7.  De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection.

Authors:  Trudie A Goers; Sabarinathan Ramachandran; Aviva Aloush; Elbert Trulock; G Alexander Patterson; Thalachallour Mohanakumar
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

8.  Antibody desensitization therapy in highly sensitized lung transplant candidates.

Authors:  L D Snyder; A L Gray; J M Reynolds; G M Arepally; A Bedoya; M G Hartwig; R D Davis; K E Lopes; W E Wegner; D F Chen; S M Palmer
Journal:  Am J Transplant       Date:  2014-02-19       Impact factor: 8.086

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.